At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 243 enrolled
Drug / intervention
darbepoetin alfa +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Once Per Cycle Treatment of Anemia With Darbepoetin Alfa With Iron in Subjects With Non Myeloid Malignancies
In Brief
A Phase 2 clinical trial evaluating darbepoetin alfa and IV iron dextran for Anemia and Non-Myeloid Malignancies. Completed, enrolled 243 participants.
Detailed Summary
To deterime the efficacy of 500 μg and 300 μg darbepoetin alfa administered subcutaneously (SC) on an every 3 weeks (Q3W) schedule, and the effect of intravenous (IV) iron supplementation in the treatment of anemia in patients with non-myeloid malignancies who were receiving multicycle chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Non-Myeloid Malignancies
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2006
Enrollment StartDec 2006
Primary CompletionDec 2007
Study CompletionMar 2008
TodayJul 2026
First PostedNov 20, 2006
Enrollment StartDec 1, 2006
Primary CompletionDec 1, 2007
Study CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 19.6 years ago
Interventions
darbepoetin alfadrug
Darbepoetin alfa administered by subcutaneous injection.
IV iron dextrandrug
Administered by intravenous (IV) injection.